These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15142180)

  • 1. The role of neuromodulation in the management of urinary urge incontinence.
    Abrams P
    BJU Int; 2004 May; 93(7):1116. PubMed ID: 15142180
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.
    Siddiqui NY; Amundsen CL; Visco AG; Myers ER; Wu JM
    J Urol; 2009 Dec; 182(6):2799-804. PubMed ID: 19837427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Update on the second line management of idiopathic overactive bladder].
    Chartier-Kastler E; Castro-Diaz D; De Ridder D; Everaert K; Sievert KD; Spinelli M; van Kerrebroeck P
    Prog Urol; 2009 Sep; 19(8):530-7. PubMed ID: 19699450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
    Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
    J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
    Chapple C; De Ridder D
    BJU Int; 2009 Nov; 104(9):1188-90. PubMed ID: 19681899
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study.
    Werner M; Schmid DM; Schüssler B
    Am J Obstet Gynecol; 2005 May; 192(5):1735-40. PubMed ID: 15902187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of neurogenic bladder in children].
    Aubert D
    Prog Urol; 2008 Mar; 18(3):172. PubMed ID: 18472071
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment on: botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.
    Kocjancic E
    Eur Urol; 2007 Sep; 52(3):858-9. PubMed ID: 17467880
    [No Abstract]   [Full Text] [Related]  

  • 9. Future directions in pelvic neuromodulation.
    Daneshgari F; Abrams P
    Urol Clin North Am; 2005 Feb; 32(1):113-5, viii. PubMed ID: 15698884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
    Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
    Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin injection therapy in the management of lower urinary tract dysfunction.
    Patel AK; Chapple CR
    Int J Clin Pract Suppl; 2006 Dec; (151):1-7. PubMed ID: 17169004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Patient follow-up after botulinum toxin intradetrusor injection. Proposal for management in neurogenic patients].
    de Sèze M; Ruffion A; Haab F; Chartier-Kastler E; Denys P; Game X; Karsenty G; Kerdraon J; Perrouin-Verbe B; Saussine C; Soler JM; Amarenco G
    Ann Readapt Med Phys; 2008 May; 51(4):315-21. PubMed ID: 18514963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
    Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
    J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing treatments for overactive bladder.
    Waine E; Stott M
    Nurs Times; 2008 Oct 14-20; 104(41):45-8. PubMed ID: 18979960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin a in the overactive bladder: current status and future directions.
    Mallina R; Sahai A; Khan MS; Dasgupta P
    BJU Int; 2007 Jun; 99(6):1549-50. PubMed ID: 17537223
    [No Abstract]   [Full Text] [Related]  

  • 16. Botulinum toxin: future developments.
    De Ridder D
    BJU Int; 2008 Jul; 102 Suppl 1():20-2. PubMed ID: 18665975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nerve stimulation boosts botulinum toxin action in spasticity.
    Frasson E; Priori A; Ruzzante B; Didonè G; Bertolasi L
    Mov Disord; 2005 May; 20(5):624-9. PubMed ID: 15726575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indications and results of intradetrusor of botulinum toxin type A injections in children].
    Dobremez E; Llanas B; Shao E; de Seze M
    Prog Urol; 2008 Mar; 18(3):168-71. PubMed ID: 18472070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin A in the overactive bladder: current status and future directions.
    Dmochowski R; Sand PK
    BJU Int; 2007 Feb; 99(2):247-62. PubMed ID: 17313422
    [No Abstract]   [Full Text] [Related]  

  • 20. Botulinum toxin--new mechanisms, new therapeutic directions?
    Chapple C; Patel A
    Eur Urol; 2006 Apr; 49(4):606-8. PubMed ID: 16457945
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.